ATLANTA, GA – – (Globe Newswire – March 6, 2026) – – A shareholder class action lawsuit has been filed against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST). The lawsuit alleges that Defendants created the false impression that Aquestive was on track to receive approval for the Company’s New Drug Application for Anaphylm by the January 31, 2026 Prescription Drug User Fee Act date.

If you purchased Aquestive shares between June 16, 2025 and January 8, 2026, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/aquestive-therapeutics/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is May 4, 2026.